3 terminated, 1 completed. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 2, Completed 1 |
| Phase 1 | 2 | Terminated 2 |
Follow Sandy Srinivas: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer Pazopanib (GW786034), Paclitaxel - Bladder Cancer, Bladder (Urothelial, Transitional Cell) Cancer | Phase 2 | Completed | Sandy Srinivas | 43 | 2010-04-01 | 2017-06-09 |
| Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer Docetaxel, Biosyn, Prednisone - Urologic Neoplasms, Prostate Cancer | Phase 1 | Terminated | Sandy Srinivas | 2 | 2010-04-01 | 2017-03-15 |
| Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer Temsirolimus, Casodex (bicalutamide) - Prostate Cancer, Prostatic Neoplasms | Phase 1 / Phase 2 | Terminated | Sandy Srinivas | 5 | 2009-10-01 | 2014-10-13 |
| Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus) Everolimus, Bevacizumab - Kidney Neoplasms, Kidney (Renal Cell) Cancer | Phase 2 | Terminated | Sandy Srinivas | 10 | 2008-08-01 | 2017-04-11 |
Neoplasm Metastasis (2) · Prostatic Neoplasms (2) · Carcinoma, Renal Cell (1) · Kidney Neoplasms (1) · Neoplasms (1) · Urinary Bladder Neoplasms (1) · Urologic Neoplasms (1)
Bevacizumab (1) · Docetaxel (1) · Everolimus (1) · Paclitaxel (1) · Prednisone (1) · bicalutamide (1) · pazopanib (1) · temsirolimus (1)
United States (4)